Clinical Trials Directory

Trials / Completed

CompletedNCT00001489

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism

Status
Completed
Phase
Study type
Observational
Enrollment
20 (planned)
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS) · NIH
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study is designed to test the effects of vigabatrin (gamma-vinyl-GABA) an experimental drug used for the treatment of epilepsy. The study will use positron emission tomography (PET scan) to detect areas of the brain receiving increased blood flow and using increased amounts of glucose. Increases in blood flow and glucose use are good indicators of brain activity. Researchers are interested in determining the effects of Vigabatrin on brain blood flow and glucose use.

Detailed description

This double-blind placebo-controlled parallel design protocol will investigate the effects of gamma-vinyl-GABA (vigabatrin--GVG) an experimental antiepileptic drug, on cerebral glucose metabolism (LCMRglc), blood flow (CBF), and seizure frequency, in patients with uncontrolled complex partial (CPS) and secondary generalized seizures (GTCS). Positron Emission Tomography (PET) will be used to measure CBF and LCMRglc.

Conditions

Timeline

Start date
1994-10-01
Completion
2000-08-01
First posted
2002-12-10
Last updated
2008-03-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00001489. Inclusion in this directory is not an endorsement.